Ann: Kazia successfully completes institutional entitlement offer, page-45

Quote from Iain Ross which was in the 1 October announcement is below. The directors will be participating in a “substantial amount” too.

“This is an inflection point for Kazia. We are about to launch into a pivotal study for paxalisib in glioblastoma, which we expect to place us on a direct path toward commercialisation. The proceeds of this transaction will be applied directly to funding the GBM AGILE clinical trial, and thereby to shape the future of our company. We invite all eligible shareholders to consider the opportunity to strengthen their position in the company as we embark on this new chapter in the development of paxalisib. The Directors of the company will each participate in a substantial amount.”